Kumar SG, Adithan C, Harish BN, Sujatha S, Roy G, Malini A. Antimicrobial resistance in India: a review. J Nat Sci Biol Med. 2013;4(2):286–91.

Article  PubMed  PubMed Central  Google Scholar 

• Divatia JV, Mehta Y, Govil D, et al. the INDICAPS-II investigators. Intensive care in India in 2018–2019: the Second Indian Intensive Care Case Mix and Practice Patterns Study. Indian J Crit Care Med. 2021;25(10):1093–1107. A Bird’s eyeview of Intensive care in India.

Kadri SS, Lai YLE, Ricotta EE, et al. External validation of difficult-to-treat resistance prevalence and mortality risk in gram-negative bloodstream infection using electronic health record data from 140 US hospitals. Open Forum Infect Dis. 2019;6.

•• Annual report January 2021 to December 2021: Antimicrobial Resistance Research and Surveillance Network: Indian Council of Medical Research.

Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25(6):1340.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Garg A, Garg J, Kumar S, Bhattacharya A, Agarwal S, Upadhyay GC. Molecular epidemiology & therapeutic options of carbapenem-resistant gram-negative bacteria. Indian J Med Res. 2019. Highlights differences between India and the West.

van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460–469.

Paul M, Carrara E, Retamar P, Tängdén T, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28(4):521–47.

Article  CAS  PubMed  Google Scholar 

Tamma P, Aitken S, Bonomo R et al. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023.

Tenover FC. Using molecular diagnostics to develop therapeutic strategies for carbapenem-resistant gram-negative infections. Front Cell Infect Microbiol. 2021;28:11.

Google Scholar 

Michalopoulos AS, Karatza DC. Multidrug-resistant gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther. 2010;8:1009–17.

Article  CAS  PubMed  Google Scholar 

Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

GLASS (Global Antimicrobial Resistance and Use Surveillance System); The detection and reporting of colistin resistance; second edition; World Health Organisation.

Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–92.

Article  CAS  PubMed  Google Scholar 

de Jonge BL, Karlowsky JA, Kazmierczak KM, et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother. 2016;60(5):3163–9.

Article  PubMed  PubMed Central  Google Scholar 

Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56:432–6.

Article  PubMed  Google Scholar 

Taha R, Kader O, Shawky S, et al. Ceftazidime-avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope. Ann Clin Microbiol Antimicrob. 2023;22:21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Veeraraghavan B, Bakthavatchalam YD, Soman R, et al. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: dosing strategy for better clinical outcome. Indian J Med Microbiol. 2021;39(3):286–8.

Article  CAS  PubMed  Google Scholar 

Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10(1):13–21.

Article  CAS  PubMed  Google Scholar 

Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and metaanalysis. Adv Ther. 2020;37(3):1049–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review. Infect Dis Ther. 2017 Jun;6(2):199–211.

Hashemian SMR, Farhadi Z, Farhadi T. Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag. 2019;15:525–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Guidance on diagnosis, management of carbapenem resistant gram-negative infections. Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi. 2022. Comprehensive  Guidelines relevant to the Indian situation.

Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care. 2014;18:229.

Article  PubMed  PubMed Central  Google Scholar 

•• Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, et al. Colistin-sparing approaches with newer antimicrobials to treat carbapenem-resistant organisms: current evidence and future prospects. Indian J Med Microbiol. 2019;37:72–90. Discusses the various options available to Indian physicians.

Article  PubMed  Google Scholar 

Bakthavatchalam YD, Walia K, Veeraraghavan B. Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: a general guidance for clinical microbiology laboratories in India. Indian J Med Microbiol. 2022;40(1):3–6.

van Duin D, Lok JJ, Earley M, et al. Antibacterial Resistance Leadership Group. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.

Hakeam HA, Alsahli H, et al. Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109: 1–7.

Pragasam AK, Veeraraghavan B, Nalini E, et al. An update on antimicrobial resistance and the role of newer antimicrobial agents for Pseudomonas aeruginosa. Indian J Med Microbiol. 2018;36:303–16.

Article  PubMed  Google Scholar 

Zhu Y, Monsel A, Roberts JA, et al. European Investigator Network for Nebulized Antibiotics in Ventilator-Associated Pneumonia (ENAVAP). Nebulized colistin in ventilator-associated pneumonia and tracheobronchitis: historical background, pharmacokinetics and perspectives. Microorganisms. 2021;9(6):1154.

Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;41(6):499–508.

Article  CAS  PubMed  Google Scholar